Advanced search
1 file | 2.12 MB Add to list

Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis : a phase I first-in-human study

Author
Organization
Abstract
Background: Nanoparticles hold considerable promise for aerosol-based intraperitoneal delivery in patients with carcinomatosis. Recently, results from preclinical and early clinical trials suggested that albumin-bound paclitaxel (ABP, Abraxane (TM)) may result in superior efficacy in the treatment of peritoneal metastases (PM) compared to the standard solvent-based paclitaxel formulation (Taxol (TM)). Here, we propose a phase I study of pressurized intraperitoneal aerosol chemotherapy (PIPAC) using ABP in patients with upper Gastrointestinal, breast, or ovarian cancer. Methods: Eligible patients with advanced, biopsy-proven PM from ovarian, breast, gastric, hepatobiliary, or pancreatic origin will undergo three PIPAC treatments using ABP with a 4-week interval. The dose of ABP will be escalated from 35 to 140 mg/m(2) using a Bayesian approach until the maximally tolerated dose is determined. The primary end point is dose-limiting toxicity. Secondary analyses include surgical morbidity, non-access rate, pharmacokinetic and pharmacodynamic analyses, quality of life, and exploratory circulating biomarker analyses. Discussion: ABP holds considerable promise for intraperitoneal aerosol delivery. The aim of this study is to determine the dose level for future randomized phase II trials using ABP in PIPAC therapy.
Keywords
NAB-PACLITAXEL, PANCREATIC ADENOCARCINOMA, CHEMOTHERAPY, CANCER, Abraxane, aerosol, albumin, carcinomatosis, intraperitoneal, pressurized, intraperitoneal aerosol chemotherapy (PIPAC)

Downloads

  • Leen PP 2018.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.12 MB

Citation

Please use this url to cite or link to this publication:

MLA
Van de Sande, Leen et al. “Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles (AbraxaneTM) for Peritoneal Carcinomatosis : a Phase I First-in-human Study.” PLEURA AND PERITONEUM 3.2 (2018): n. pag. Print.
APA
Van de Sande, L., Graversen, M., Hubner, M., Pocard, M., Reymond, M., Vaira, M., Cosyns, S., et al. (2018). Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (AbraxaneTM) for peritoneal carcinomatosis : a phase I first-in-human study. PLEURA AND PERITONEUM, 3(2).
Chicago author-date
Van de Sande, Leen, Martin Graversen, Martin Hubner, Marc Pocard, Marc Reymond, Marco Vaira, Sarah Cosyns, Wouter Willaert, and Wim Ceelen. 2018. “Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles (AbraxaneTM) for Peritoneal Carcinomatosis : a Phase I First-in-human Study.” Pleura and Peritoneum 3 (2).
Chicago author-date (all authors)
Van de Sande, Leen, Martin Graversen, Martin Hubner, Marc Pocard, Marc Reymond, Marco Vaira, Sarah Cosyns, Wouter Willaert, and Wim Ceelen. 2018. “Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles (AbraxaneTM) for Peritoneal Carcinomatosis : a Phase I First-in-human Study.” Pleura and Peritoneum 3 (2).
Vancouver
1.
Van de Sande L, Graversen M, Hubner M, Pocard M, Reymond M, Vaira M, et al. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (AbraxaneTM) for peritoneal carcinomatosis : a phase I first-in-human study. PLEURA AND PERITONEUM. 2018;3(2).
IEEE
[1]
L. Van de Sande et al., “Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (AbraxaneTM) for peritoneal carcinomatosis : a phase I first-in-human study,” PLEURA AND PERITONEUM, vol. 3, no. 2, 2018.
@article{8583490,
  abstract     = {Background: Nanoparticles hold considerable promise for aerosol-based intraperitoneal delivery in patients with carcinomatosis. Recently, results from preclinical and early clinical trials suggested that albumin-bound paclitaxel (ABP, Abraxane (TM)) may result in superior efficacy in the treatment of peritoneal metastases (PM) compared to the standard solvent-based paclitaxel formulation (Taxol (TM)). Here, we propose a phase I study of pressurized intraperitoneal aerosol chemotherapy (PIPAC) using ABP in patients with upper Gastrointestinal, breast, or ovarian cancer. 
Methods: Eligible patients with advanced, biopsy-proven PM from ovarian, breast, gastric, hepatobiliary, or pancreatic origin will undergo three PIPAC treatments using ABP with a 4-week interval. The dose of ABP will be escalated from 35 to 140 mg/m(2) using a Bayesian approach until the maximally tolerated dose is determined. The primary end point is dose-limiting toxicity. Secondary analyses include surgical morbidity, non-access rate, pharmacokinetic and pharmacodynamic analyses, quality of life, and exploratory circulating biomarker analyses. 
Discussion: ABP holds considerable promise for intraperitoneal aerosol delivery. The aim of this study is to determine the dose level for future randomized phase II trials using ABP in PIPAC therapy.},
  articleno    = {20180112},
  author       = {Van de Sande, Leen and Graversen, Martin and Hubner, Martin and Pocard, Marc and Reymond, Marc and Vaira, Marco and Cosyns, Sarah and Willaert, Wouter and Ceelen, Wim},
  issn         = {2364-7671},
  journal      = {PLEURA AND PERITONEUM},
  keywords     = {NAB-PACLITAXEL,PANCREATIC ADENOCARCINOMA,CHEMOTHERAPY,CANCER,Abraxane,aerosol,albumin,carcinomatosis,intraperitoneal,pressurized,intraperitoneal aerosol chemotherapy (PIPAC)},
  language     = {eng},
  number       = {2},
  pages        = {5},
  title        = {Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis : a phase I first-in-human study},
  url          = {http://dx.doi.org/10.1515/pap-2018-0112},
  volume       = {3},
  year         = {2018},
}

Altmetric
View in Altmetric